Bariatric News is teaming with Medtronic on this World Obesity Day on 4th March and asking you to join the global community to raise awareness on obesity as a chronic disease, its causes and consequences, and call for action for improved prevention and treatment.
Eiger BioPharmaceuticals has announced positive results from the Phase 2 PREVENT study of Avexitide in patients with severe Post-Bariatric Hypoglycaemia (PBH), the outcomes were published in Journal of Clinical Endocrinology & Metabolism (Craig, C.M. et al, 2021).
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug.
W L Gore & Associates (Gore) has launched the GORE Synecor Intraperitoneal Biomaterial in Europe, the Middle East and South Africa. The device was designed to address unmet needs in complex hernia repair, providing rapid vascularity and permanent strength with a low profile for single, effective hernia repair. The GORE SYNECOR Intraperitoneal Biomaterial is conceived for ease of use during laparoscopic, robotic and open surgical procedures.
A research group from Mind, Brain and Behaviour Research Centre (CIMCYC) of the University of Granada (UGR) has been studying the issue of excess weight from a neuroscientific perspective for many years, to determine the precise role played by the brain.
A new analytical technique is allowing scientists are getting a clearer view of the microenvironments found within adipose tissue associated with obesity. This advance may illuminate why some adipose tissues are more prone to inflammation - leading to diseases like type 2 diabetes, cancer and cardiovascular disorders - and help direct future drug therapies to treat obesity.
Scientists used accelerometers to track daily activity levels for a week in 89 adults with obesity or overweight and, in a series of tests, measured their ability to multitask and maintain their attention despite distractions. The study revealed that individuals who spent more sedentary time in bouts lasting 20 minutes or more were less able to overcome distractions.
Scientists from Arizona State University and Oklahoma State University have reported that not all overweight and obesity body shapes are equally stigmatised. Unfortunately, fat stigma is a socially acceptable form of prejudice that contributes to poor medical outcomes and negatively affects educational and economic opportunities. This latest study has shown that women with abdominal fat around their midsection are more stigmatised than those with gluteofemoral fat on the hips, buttocks and thighs.
Researchers from UCL Institute of Cardiovascular Science and the UCL MRC Unit for Lifelong Health & Ageing, London, UK, who analysed data from the UK Biobank of 500,000 people aged 58 years on average, found that people with higher than normal blood sugar levels were 42% more likely to experience cognitive decline over an average of four years. They were also 54% more likely to develop vascular dementia over an average of eight years, although absolute rates of both cognitive decline and dementia were low.
Outcomes form the investigator-initiated INSPIRE clinical trial, conducted in collaboration with Fractyl, have demonstrate that a majority of patients with type 2 diabetes treated with a combination of Revita DMR (duodenal mucosal resurfacing) and a glucagon-like peptide-1 receptor agonist (GLP-1RA) were able to discontinue and remain off insulin therapy for 18 months after treatment. Additionally, all treated patients showed significant improvements in measures of glucose regulation and metabolic health.